Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2026Pharmaceutical Statistics

BEACON : An Adaptive Bayesian Early‐Phase Oncology Trial Design Integrating Dose Optimization and Proof‐of‐Concept Across Survival and Binary Endpoints

View Full Paper
Ask AI
Bookmark
Share

Authors

YTYike TangBristol-Myers Squibb (United States)FTFeng TianXZXiaochen ZhuBristol-Myers Squibb (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tang et al. (2026) studied this question.

synapsesocial.com/papers/6abdf87766f375461851713fhttps://doi.org/10.1002/pst.70127
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SAM: Self-Adapting Mixture Prior to Dynamically Borrow Information from Historical Data in Clinical Trials2023 · 37 citations
  2. 2Evaluating water quality using power priors to incorporate historical information2005 · 175 citations
  3. 3BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints2017 · 132 citations
  4. 4DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials2023 · 3 citations
  5. 5Robust meta‐analytic‐predictive priors in clinical trials with historical control information2014 · 453 citations